Cargando…

Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer

BACKGROUND: It is known that gut microbiota can regulate cancer therapies. We hypothesized that gut microbiota may interact with androgen deprivation therapy (ADT) in the process of castration-resistant prostate cancer (CRPC). Here, the differences in gut microbiota between matched hormone-sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yufei, Jiang, Haowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658119/
https://www.ncbi.nlm.nih.gov/pubmed/33209658
http://dx.doi.org/10.21037/tau-20-566
_version_ 1783608598336634880
author Liu, Yufei
Jiang, Haowen
author_facet Liu, Yufei
Jiang, Haowen
author_sort Liu, Yufei
collection PubMed
description BACKGROUND: It is known that gut microbiota can regulate cancer therapies. We hypothesized that gut microbiota may interact with androgen deprivation therapy (ADT) in the process of castration-resistant prostate cancer (CRPC). Here, the differences in gut microbiota between matched hormone-sensitive prostate cancer (HSPC) and CRPC were determined before and after ADT. METHODS: We profiled the fecal microbiota in matched HSPC and CRPC from 21 patients who received ADT at our urological center using 16S rRNA gene amplicon sequencing. Differences in microbiota were determined with α/β-diversity and LefSe analysis. Functional inference of microbiota was performed with PICRUSt. RESULTS: The results showed that the gut microbial community in CRPC was significantly altered with increased abundance of several bacterial flora including genus Phascolarctobacterium and Ruminococcus. For functional analyses, bacterial gene pathways involved in terpenoids/polyketides metabolism and ether lipid metabolism were significantly activated in CRPC. CONCLUSIONS: Measurable differences in the gut microbiota were identified between HSPC and CRPC. Functional validations are further needed to ascertain the underlying mechanism of these differential microbiota in the process of CRPC, and their potential as new targets to enhance ADT responses.
format Online
Article
Text
id pubmed-7658119
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76581192020-11-17 Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer Liu, Yufei Jiang, Haowen Transl Androl Urol Original Article BACKGROUND: It is known that gut microbiota can regulate cancer therapies. We hypothesized that gut microbiota may interact with androgen deprivation therapy (ADT) in the process of castration-resistant prostate cancer (CRPC). Here, the differences in gut microbiota between matched hormone-sensitive prostate cancer (HSPC) and CRPC were determined before and after ADT. METHODS: We profiled the fecal microbiota in matched HSPC and CRPC from 21 patients who received ADT at our urological center using 16S rRNA gene amplicon sequencing. Differences in microbiota were determined with α/β-diversity and LefSe analysis. Functional inference of microbiota was performed with PICRUSt. RESULTS: The results showed that the gut microbial community in CRPC was significantly altered with increased abundance of several bacterial flora including genus Phascolarctobacterium and Ruminococcus. For functional analyses, bacterial gene pathways involved in terpenoids/polyketides metabolism and ether lipid metabolism were significantly activated in CRPC. CONCLUSIONS: Measurable differences in the gut microbiota were identified between HSPC and CRPC. Functional validations are further needed to ascertain the underlying mechanism of these differential microbiota in the process of CRPC, and their potential as new targets to enhance ADT responses. AME Publishing Company 2020-10 /pmc/articles/PMC7658119/ /pubmed/33209658 http://dx.doi.org/10.21037/tau-20-566 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Liu, Yufei
Jiang, Haowen
Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
title Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
title_full Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
title_fullStr Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
title_full_unstemmed Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
title_short Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
title_sort compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658119/
https://www.ncbi.nlm.nih.gov/pubmed/33209658
http://dx.doi.org/10.21037/tau-20-566
work_keys_str_mv AT liuyufei compositionaldifferencesofgutmicrobiomeinmatchedhormonesensitiveandcastrationresistantprostatecancer
AT jianghaowen compositionaldifferencesofgutmicrobiomeinmatchedhormonesensitiveandcastrationresistantprostatecancer